Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, 24-52-week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, and Safety of Saredutant 100 mg Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients With Major Depressive Disorder

NCT00336713 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00336713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, 24-52-week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, and Safety of Saredutant 100 mg Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients With Major Depressive Disorder
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
April 30, 2008
Enrollment
430 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder